Skip to content
Clinical Trials – home
Therapeutic area

Gastrointestinal disorders – page 46

  • 1 133 clinical trials
  • 489 recruiting
  • 474 conditions
  • 28 countries

Conditions in this area

474 conditions with trials, the busiest first

Clinical trials in Gastrointestinal disorders

1 133 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 133 clinical trials

Pancreatic carcinoma

Not yet recruiting

Phase II/III trial of autologous dendritic cells loaded with allogenic mesothelioma lysate in patients with borderline resectable pancreatic cancer

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Autologous dendritic cells loaded with allogenic allogeneic lysate of mesothelioma cell lines
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Systemic scleroderma

Not yet recruiting

Rituximab versus placebo for maintenance therapy in adults with stabilized systemic sclerosis‑associated interstitial lung disease

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
  • Sponsor:Assistance Publique Hopitaux De Paris

Systemic scleroderma

Not yet recruiting

Lebrikizumab in Adults with Moderate to Severe Localized Scleroderma

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Lebrikizumab
  • Sponsor:Charite Universitaetsmedizin Berlin KöR

Colon cancer

Not yet recruiting

Pembrolizumab for Patients with Localised dMMR Colon Cancer: Neoadjuvant and Organ-Sparing Treatment Study

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Region Sjaelland

Gastric cancer

Not yet recruiting

68Ga-FAPI-46 PET-CT for Initial Staging of Gastric Cancer in Patients Eligible for Curative Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:(S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-Cyano-4,4-Difluoropyrrolidin-1-Yl)-2-Oxoethylcarbamoyl)-Quinolin-6-Yl)(Methyl)Amino)-Propyl)Piperazin-1-Yl)-2-Oxoethyl)-68Ga-[1,4,7,10]-Tetraazacyclododecane-1,4,7-Triyl)Triacetate
  • Sponsor:Centre Hospitalier Universitaire De Bordeaux

A study to evaluate the effectiveness of ispaghula husk in patients with low anterior resection syndrome after rectal cancer surgery

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Ispaghula husk

Colitis ulcerative

Not yet recruiting

A study comparing vedolizumab, filgotinib, ustekinumab, and infliximab to maintain remission in patients with ulcerative colitis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Filgotinib
  • Sponsor:University Hospital Of Clermont-Ferrand

Rectal cancer

Not yet recruiting

A study of botulinum toxin type A versus placebo to treat bowel movement problems in patients recovering from surgery for rectal cancer

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Botulinum Toxin Type A
  • Sponsor:UZ Leuven

Colitis ulcerative

Not yet recruiting

Study on the use of oral vancomycin for children with ulcerative colitis

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:0–17 years
  • Substances:Vancomycin Hydrochloride
  • Sponsor:Pirkanmaan hyvinvointialue

Stomatitis

Not yet recruiting

Comparison of esketamine hydrochloride mouthwash and intravenous esketamine to reduce pain from oral mucositis in patients undergoing hematopoietic stem cell transplantation

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Esketamine
  • Sponsor:Amsterdam UMC Stichting

Sjogren's syndrome

Not yet recruiting

A study to evaluate the effect of obinutuzumab on removing specific immune cells in the tissues of patients with Sjögren's syndrome.

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:Stichting Radboud universitair medisch centrum

Colorectal cancer

Not yet recruiting

A study to evaluate the safety and effectiveness of oxaliplatin delivered directly to the liver for patients with colorectal cancer and liver metastasis

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Oxaliplatin
  • Sponsor:UZ Leuven

Substances studied in this area

The therapies tested most often in Gastrointestinal disorders trials.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.